City Therapeutics, Inc.

City Therapeutics, Inc. (CTY) priced its initial public offering on Oct 16, 2026 at $18.00 per share, raising $200M, and listed on Nasdaq Global Market. At the IPO price its market capitalization was about $931M. Goldman Sachs was lead-left underwriter, joined by Jefferies, Stifel and Oppenheimer. Goodwin Procter advised the company and Cooley advised the underwriters.

CITY THERAPEUTICS, INC. is a clinical-stage biotechnology company developing RNA interference (RNAi) therapeutics designed to silence the expression of disease-relevant proteins, using its City Platform.

Status

IPO

Ticker

CTY

Exchange

Nasdaq Global Market

Priced

Oct 16, 2026

IPO price

$18.00

Raised

$200M

Market cap at IPO price

$931M

First filed

Sep 24, 2026

Underwriters

Goldman Sachs, Jefferies, Stifel and Oppenheimer

Company counsel

Goodwin Procter

Underwriters' counsel

Cooley

Sector

Biotech & pharma

Country / state

MA

Market cap at IPO price = shares outstanding after the offering (all classes, before the over-allotment option) × the IPO price, from the final prospectus.